COMPARE · Data as of August 27, 2026
BSX vs MDLN
Verdict: Side-by-side breakdown using the Bull Rankings model. BSX scored 79.0, MDLN scored 46.3 — BSX leads.
Compare another set
Different reporting periods. BSX's fundamentals are as of June 2026, but MDLN's are as of December 2025 — a 6-month gap. Growth, margin and valuation figures below therefore describe different windows and aren't strictly like-for-like.
BSX
Boston Scientific Corporation
79
$47.43 · $68.7B
fundamentals as of
Score gap
32.7
BSX leads
MDLN
Medline Inc.
46.3
$37.35 · $66.5B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- CheapestBSX19.2x
- Fastest growthBSX+13.5%
- Strongest balance sheetBSX0.50
- Highest qualityBSX71 / 100
- Largest discount to fair valueBSX-17%
Side by side · every name on one set of axes
The model, pillar by pillar (0–100 each)
BSX
stronger →← stronger
MDLN
71
Qualityreturns · margins · balance sheet
48
88
Growthrevenue & earnings expansion
85
79
Valuevaluation vs sector peers
24
BSX is stronger on 3 of 3 pillars.
Fundamentals, head-to-head
BSX
MDLN
$3.6bB
FCF
$1.3bC+
+13.5%B+
Rev
+11.5%B
0.50B
D/E
0.65C+
19.2xA-
P/E
32.8xC+
0.72A-
PEG
3.20D
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
BSX
MDLN
17% below
Price vs fair valuelower is cheaper
198% above
~-1%/yr
Growth the price implies10-yr FCF · lower = less priced in
~35%/yr
+19%
1-yr DCF upside
-69%
+20%
5-yr DCF upside
-66%
+23%
10-yr DCF upside
-62%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
BSX
Why this score
- Buying back stock
MDLN
Why this score
- Short track record
The companies
BSXBoston Scientific Corporation
Why now
Medical Devices · market cap $68.7b. Down 57% from 52-week high of $109.50 — deep drawdown territory. Revenue growing +14%, comfortably above the S&P median. PEG 0.72 — paying under fair value for the growth rate. 29 sell-side analysts rate this a Buy with a mean 1-yr target of $62.69 (implying +32% upside).
Moat
Net margin 17% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 15% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 99% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Down 57% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
MDLNMedline Inc.
Why now
Medical Instruments & Supplies · market cap $66.5b. Down 27% from 52-week high of $50.88 — deep drawdown territory. Revenue growing +11%, comfortably above the S&P median. 26 sell-side analysts rate this a Buy with a mean 1-yr target of $50.92 (implying +36% upside).
Moat
ROE 10% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 112% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. $66.5b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk
Trailing P/E 33x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. Net margin 4.1% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where BSX and MDLN diverge
On the headline score the gap is 32.7 points in favor of BSX. The widest single difference is Value, where BSX leads by 54.1 points.
- ValueBSX 78.5 · MDLN 24.4BSX +54.1
- QualityBSX 71.2 · MDLN 47.8BSX +23.4
- GrowthBSX 88.4 · MDLN 85.1BSX +3.3
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.